Related Experiment Video
Updated: Aug 12, 2026
06:01
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke
J Staton1, M Sayer, G J Hankey
1Department of Hematology, Royal Perth Hospital, Perth, Australia.
Stroke
|May 10, 2005
Summary
Higher protein Z concentrations are linked to an increased risk of ischemic stroke. This study investigated protein Z gene polymorphisms (A-13G, G79A) and their association with stroke risk, finding a causal link between elevated protein Z levels and stroke.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Research
- Biochemistry
Background:
- Protein Z is a key determinant of plasma protein Z concentrations.
- Genetic variations in the protein Z gene, specifically A-13G and G79A polymorphisms, may influence stroke risk.
- Understanding these genetic factors is crucial for assessing ischemic stroke risk.
Purpose of the Study:
- To investigate the association between protein Z gene polymorphisms (A-13G and G79A) and the risk of ischemic stroke.
- To determine if protein Z blood concentrations are linked to ischemic stroke risk.
- To explore the relationship between specific protein Z genotypes and plasma protein Z levels.
Main Methods:
- A case-control study involving 151 ischemic stroke patients and 164 community controls.
- Genotyping for A-13G promoter and G79A intron F polymorphisms of the protein Z gene.
- Measurement of plasma protein Z concentrations at two time points post-stroke.
Main Results:
- Plasma protein Z concentrations were significantly higher in ischemic stroke cases than controls.
- Protein Z levels varied significantly across different genotypes for both A-13G and G79A polymorphisms.
- While genotype prevalence did not differ, pooled analysis suggested a progressively lower odds of ischemic stroke with the G79A AA genotype compared to GG.
Conclusions:
- Elevated plasma protein Z concentrations are causally associated with an increased risk of ischemic stroke.
- The study provides consistent evidence linking protein Z genotypes, concentrations, and stroke risk.
- Further research may elucidate the precise mechanisms underlying this association.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...